Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 8/20 | 0.54 |
| ▸ | CALCR | P30988 | 8/20 | 0.54 |
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.53 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.53 |
| ▸ | NPY2R | P49146 | 7/20 | 0.53 |
| ▸ | NPY4R | P50391 | 7/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.53 |
| ▸ | NPY1R | P25929 | 5/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30512588 | 0.91 | RAMP3 (0.53) | RAMP3CALCRNMUR2NMUR1CXCR4 | |
| SCHEMBL30423163 | 0.88 | RAMP3 (0.60) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30039566 | 0.87 | NMUR2 (0.53) | RAMP3CALCRNMUR2NMUR1NPY2R | |
| SCHEMBL30526237 | 0.87 | NPY2R (0.60) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL30988900 | 0.87 | NMUR2 (0.52) | RAMP3CALCRNMUR2NMUR1 | |
| SCHEMBL30883225 | 0.86 | NMUR2 (0.54) | RAMP3CALCRNMUR2NMUR1NPY2R | |
| SCHEMBL29353296 | 0.85 | NPY2R (0.47) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31663834 | 0.85 | RAMP3 (0.58) | RAMP3CALCRNMUR2NMUR1NPY2R | |
| SCHEMBL31031561 | 0.85 | NPY2R (0.52) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL31031583 | 0.85 | RAMP3 (0.58) | RAMP3CALCRNMUR2NMUR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-11719697-B2 | Immunoassay and antibodies for the detection of chromogranin A | CEZANNE S.A.S. (FR) | 2023-08-08 | — | — | US | disclosed |
| US-20230086542-A1 | COMPOSITIONS FOR ENDOMETRIOSIS ASSESSMENT HAVING IMPROVED SPECIFICITY | ASPIRA WOMEN'S HEALTH INC. (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4107525-A1 | COMPOSITIONS FOR ENDOMETRIOSIS ASSESSMENT HAVING IMPROVED SPECIFICITY | Aspira Women's Health Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| CN-110161252-B | Novel markers for assessing the risk of progression of cardiovascular disorders | 赛诺菲-安万特德国有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-114957436-A | Recombinant NINJ2 protein, gene for encoding protein, preparation method and pharmaceutical composition | 华中科技大学 | 2022-08-30 | — | — | CN | disclosed |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-114269780-A | Novel anti-PD-L1 antibody and application thereof | 北京先通生物医药技术有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | RAMP3 143/4885CALCR 1974/4885NMUR2 920/4885 |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | RAMP3 562/4885CALCR 4470/4885NMUR2 2636/4885 |
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | RAMP3 410/4885CALCR 118/4885NMUR2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.